newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

  • Intellia Therapeutics will present new clinical data for its CRISPR-based therapy nex-z at two medical meetings in November 2026.
  • A Phase 1 analysis of cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN & mixed phenotype will be presented at the American Heart Association Scientific Sessions on November 9 in Chicago.
  • Up to four years of follow-up data regarding long-term durability, outcomes, & safety will be presented at the International Society of Amyloidosis Symposium on November 18 in Montevideo, Uruguay.
  • The AHA presentation titled "Cardiac Outcomes Following a Single Dose of Nexiguran Ziclumeran..." will be a moderated digital poster presented by Yousuf Razvi.
  • The ISA presentation titled "Long-Term Durability, Outcomes, and Safety of Nexiguran Ziclumeran Gene Editing..." will be an e-poster presented by Julian Gillmore.
  • Both presentations will be accessible on Intellia's Scientific Publications & Presentations page starting at the beginning of each respective session.
  • Nex-z is designed to inactivate the TTR gene & is currently being investigated in Phase 3 MAGNITUDE & MAGNITUDE-2 trials for ATTR-CM & ATTRv-PN.
  • The therapy has received Orphan Drug & RMAT Designations from the FDA, as well as Orphan Drug Designation from the European Commission.
  • Intellia leads the development & commercialization of nex-z in collaboration with Regeneron Pharmaceuticals.